France: Reimbursement Review Launched for Spinal Neurostimulation Devices
France's cost containment agency (HAS) is undertaking a health technology assessment review of all implantable spinal neurostimulation devices, whether rechargeable or not, that are intended for the treatment of chronic pain and are currently on the national List of Reimbursable Products and Services (PBDA).
The review is being done at the request of the Ministry of Health, it said.
The review will result in an updated reimbursement list based on an assessment of each device's effectiveness and the value of its therapeutic indications. A working group will review published scientific literature and data provided by industry as well as advice from health professionals who have experience with such devices. HAS will publish a notice for public comment seeking input from all stakeholders including patients.